Fundraising Fox
Aegle Therapeutics
Woburn, US · Delaware corporation · 4 known investors
Find your way into Aegle Therapeutics
Sign up to see every warm intro you have to Aegle Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aegle Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
Founders & leadership
SA
Shelley A. HartmanCo-founder & CEOShelley Hartman is co-founder and CEO of Aegle Therapeutics, a clinical-stage biotech company developing extracellular vesicle therapies. She previously served as chairman and CEO of LifeSync Holdings and CEO of LifeSync Corporation, a medical device company, and worked as a managing director in the investment banking division at Goldman Sachs focused on healthcare.
EV
Evangelos V. BadiavasFounder & Chief Scientific Officer
HK
Heidi KempinskiChief Operational OfficerHeidi Kempinski serves as Chief Operating Officer at Aegle Therapeutics. She has held senior operational and strategic roles in biopharmaceutical organizations, with experience spanning drug development, R&D operations, corporate strategy, and mergers and acquisitions.
KM
Kathleen MurphyHead of Clinical Operations
RW
Robert Williamson, Jr.Named on SEC filing
RR
Robert RyanNamed on SEC filing
LM
Leon Moulder, Jr.Named on SEC filing
Board
MT
Mikio TanjiBoard director
EB
DS
David SchimelBoard director
SB
Scott BraunsteinBoard director
LM
Leon MoulderBoard director
Investors · 4
DEFTA Partnerslisted by DEFTA PartnersSan Francisco
How we know: DEFTA Partners's portfolio page · Not right? Tell us
New World Angelslisted by New World AngelsBoca Raton
How we know: New World Angels's portfolio page · funding news · newworldangels.com · Not right? Tell us
Ocean Azul Partnerslisted by Ocean Azul PartnersCoral Gables · $500K – $2M
How we know: Ocean Azul Partners's portfolio page · the VCSheet dataset · Not right? Tell us
DeepWork CapitalreportedOrlando
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.2M disclosed across 3 of 4 rounds · 2020–2026
▶$2.3MraisedAug 2026 · 17 investors · BiotechnologyRule 506(b)
▶$2.3MraisedAug 2026 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shelley HartmanExecutive Officer, Director
- Scott BraunsteinDirector
- Leon MoulderDirector
- Evangelos BadiavasDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455.7KraisedMar 2026 · 10 investors · BiotechnologyRule 506(b)
▶$455.7KraisedMar 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evangelos BadiavasDirector
- Shelley HartmanExecutive Officer, Director
- David SchimelDirector
- Scott BraunsteinDirector
- Leon MoulderDirector
- Mikio TanjiDirector
- Steve O'HaraDirector
- Offering amount
- $700K
- Amount sold
- $455.7K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJul 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shelley HartmanExecutive Officer, Director
- Evangelos BadiavasExecutive Officer, Director
- Robert Williamson, Jr.Executive Officer, Director
- David SchimelDirector
- Robert RyanDirector
- Elona BaumDirector
- Leon Moulder, Jr.Director
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Egle TherapeuticsEgle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Apogee TherapeuticsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
AegleAegle Capital, a trade name of Aegle Health Partners, Inc., provides financing for commercial healthcare businesses. The firm focuses on healthcare-sector capital.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies working in the same space as Aegle Therapeutics.
In the news
Frequently asked questions
- What does Aegle Therapeutics do?
- Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
- Who founded Aegle Therapeutics?
- Aegle Therapeutics was founded by Shelley A. Hartman, Evangelos V. Badiavas.
- Who are Aegle Therapeutics's investors?
- Aegle Therapeutics's investors include DEFTA Partners, New World Angels, Ocean Azul Partners, DeepWork Capital.
- How much funding has Aegle Therapeutics raised?
- Aegle Therapeutics has disclosed $9.2M raised across 3 of its 4 known rounds.
- Where is Aegle Therapeutics headquartered?
- Aegle Therapeutics is headquartered in Woburn, US.